An epidemiological study of risk factors for lung cancer in Guangzhou, China

Du, Ying-xiu; Cha, Qing; Chen, Xiaowei; Chen, Yongzhong; Huang, Lan-Fang; Feng, Zhiqiang; Wu, Xia-fen; Wu, Joseph M.

doi:10.1016/s0169-5002(96)90208-1

Cited by 70 publications

(46 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although lung cancer incidence and mortality rates continue to decline in the West, the same does not hold true for China and Japan, where the principle risk factors of smoking, air pollution, and an ageing population contribute to increasing incidence (19). Indeed, geographical differences also appear to exist in disease histology with a higher prevalence of adenocarcinoma in Japan than in most Western countries (20,21).…”

Section: Introductionmentioning

confidence: 99%

Translating the Therapeutic Potential of AZD4547 in FGFR1-Amplified Non–Small Cell Lung Cancer through the Use of Patient-Derived Tumor Xenograft Models

Zhang

et al. 2012

Clinical Cancer Research

149

119

View full text Add to dashboard Cite

Purpose: To investigate the incidence of FGFR1 amplification in Chinese non-small cell lung cancer (NSCLC) and to preclinically test the hypothesis that the novel, potent, and selective fibroblast growth factor receptor (FGFR) small-molecule inhibitor AZD4547 will deliver potent antitumor activity in NSCLC FGFR1-amplified patient-derived tumor xenograft (PDTX) models.Experimental Design: A range of assays was used to assess the translational relevance of FGFR1 amplification and AZD4547 treatment including in vitro lung cell line panel screening and pharmacodynamic (PD) analysis, FGFR1 FISH tissue microarray (TMA) analysis of Chinese NSCLC (n ¼ 127), and, importantly, antitumor efficacy testing and PD analysis of lung PDTX models using AZD4547.Results: The incidence of FGFR1 amplification within Chinese patient NSCLC tumors was 12.5% of squamous origin (6 of 48) and 7% of adenocarcinoma (5 of 76). AZD4547 displayed a highly selective profile across a lung cell line panel, potently inhibiting cell growth only in those lines harboring amplified FGFR1 (GI 50 ¼ 0.003-0.111 mmol/L). AZD4547 induced potent tumor stasis or regressive effects in four of five FGFR1-amplified squamous NSCLC PDTX models. Pharmacodynamic modulation was observed in vivo, and antitumor efficacy correlated well with FGFR1 FISH score and protein expression level.Conclusions: This study provides novel epidemiologic data through identification of FGFR1 gene amplification in Chinese NSCLC specimens (particularly squamous) and, importantly, extends the clinical significance of this finding by using multiple FGFR1-amplified squamous lung cancer PDTX models to show tumor stasis or regression effects using a specific FGFR inhibitor (AZD4547). Thus, the translational science presented here provides a strong rationale for investigation of AZD4547 as a therapeutic option for patients with squamous NSCLC tumors harboring amplification of FGFR1. Clin Cancer Res; 18(24); 6658-67. Ó2012 AACR.

show abstract

Section: Introductionmentioning

confidence: 99%

Translating the Therapeutic Potential of AZD4547 in FGFR1-Amplified Non–Small Cell Lung Cancer through the Use of Patient-Derived Tumor Xenograft Models

Zhang

et al. 2012

Clinical Cancer Research

149

119

View full text Add to dashboard Cite

show abstract

“…The authors concluded that, despite some methodologic limitations, the epidemiologic studies together with experimental evidence and pathogenesis provide compelling evidence of causality for ARI and COPD, particularly in conjunction with findings for environmental tobacco smoke and ambient air pollution. The relationship between coal smoke (but not biomass) and lung cancer has also been consistently established in a number of epidemiologic studies (52)(53)(54)(55). For other health outcomes, including asthma, upper aerodigestive cancer, interstitial lung disease, low birth weight, perinatal mortality, tuberculosis, and eye diseases, Bruce et al (10) classified the evidence as more tentative [moderate or weak as classified by Smith et al (14) and Smith (56)], although a more recent study further confirms the relationship with low birth weight (13).…”

Section: Current Researchmentioning

confidence: 86%

The health impacts of exposure to indoor air pollution from solid fuels in developing countries: knowledge, gaps, and data needs.

Ezzati

Kammen

2002

Environ Health Perspect

389

268

View full text Add to dashboard Cite

Globally, almost 3 billion people rely on biomass (wood, charcoal, crop residues, and dung) and coal as their primary source of domestic energy. Exposure to indoor air pollution (IAP) from the combustion of solid fuels is an important cause of morbidity and mortality in developing countries. In this paper, we review the current knowledge on the relationship between IAP exposure and disease and on interventions for reducing exposure and disease. We take an environmental health perspective and consider the details of both exposure and health effects that are needed for successful intervention strategies. We also identify knowledge gaps and detailed research questions that are essential in successful design and dissemination of preventive measures and policies. In addition to specific research recommendations, we conclude that given the interaction of housing, household energy, and day-to-day household activities in determining exposure to indoor smoke, research and development of effective interventions can benefit tremendously from integration of methods and analysis tools from a range of disciplines in the physical, social, and health sciences.

show abstract

“…In particular, gender differences in nicotine metabolism [15±17], male/female variations in cytochrome P-450 enzymes [18,19], and hormonal effects have been investigated [20±22]. Genetic [23,24] and exogenous factors, such as passive smoking or indoor air pollution [25,26] may also play a greater role in females. In Germany, 24% of all nonsmoking females live with a smoking male and are exposed to passive smoking [27].…”

Section: Discussionmentioning

confidence: 99%

Lung cancer in young females

Lienert¹,

Serke²,

Schönfeld³

et al. 2000

European Respiratory Journal

View full text Add to dashboard Cite

Previous studies suggested that the characteristics of young female lung cancer patients may differ from those of other patients. Using the cancer registry at the Lungenklinik Heckeshorn hospital, all female patients under the age of 46 yrs with primary lung cancer 1986±1995 were identified. The clinical records were reviewed for risk factors, stage, histology, therapy, and survival. The data were compared with those of other patients.Of the 4,939 patients 96 (1.9%) were females aged <46 yrs. The percentage of young females doubled within ten years from 1 to 2% of all patients (p=0.03). The main risk factor in young females was smoking. Adenocarcinoma and carcinoids were overrepresented, whereas squamous cell and small cell carcinoma were significantly rarer in the young female group. Young females and young males were more likely to have advanced disease and underwent surgery and/or combined treatment significantly more often than older patients. The overall survival was only moderately better in younger patients.The clinical features of young female patients differed from those of young males and older females, the prognosis likewise depended on tumour stage and therapy. Eur Respir J 2000; 16: 986±990.

show abstract

An epidemiological study of risk factors for lung cancer in Guangzhou, China

Cited by 70 publications

References 3 publications

Translating the Therapeutic Potential of AZD4547 in FGFR1-Amplified Non–Small Cell Lung Cancer through the Use of Patient-Derived Tumor Xenograft Models

Translating the Therapeutic Potential of AZD4547 in FGFR1-Amplified Non–Small Cell Lung Cancer through the Use of Patient-Derived Tumor Xenograft Models

The health impacts of exposure to indoor air pollution from solid fuels in developing countries: knowledge, gaps, and data needs.

Lung cancer in young females

Contact Info

Product

Resources

About